Results 251 to 260 of about 69,773 (297)

Rare internal malignancies in xeroderma pigmentosum: A report of two cases from Tunisia and analysis of driver mutations. [PDF]

Cancer Pathog Ther
Rammeh S, Ben Taher Y, Ben Rekaya M, Ben Rejeb S, Lahmar A, Jones M, Zeglaoui F, Belguith N.   +7 more
europepmc   +1 more source

Key institutional issues and possible scenarios for the review of the EC electronic communications framework [PDF]

Larouche, P., Visser, M.C.B.F. de
core   +1 more source

RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. [PDF]

Cancer Immunol Res
Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, Ospina OE, Chow C, Seu L, Rose OL, Hegde A, Khushalani NI, Quintana E, Smalley KSM.   +13 more
europepmc   +1 more source

Impact of melanoma histological regression on first‐line immunotherapy response in stage‐IV disease

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page e342-e345, May 2026.
Jean‐Baptiste Such, Sandrine Mansard, Mélissa Zlobecki, Carole Chevenet, Céline Lambert, Marie Bachelerie, Jacques Rouanet   +6 more
wiley   +1 more source

Effect of sex differences on the emergence of ctDNA RAS mutations in RAS wild-type colorectal cancer. [PDF]

Sci Rep
Iguchi K, Uchiyama M, Asari M, Numata K, Shiozawa M.   +4 more
europepmc   +1 more source

Genomic profiling of AKT1 and NRAS mutations using NGS in Egyptian hepatocellular carcinoma. [PDF]

Discov Oncol
Mohmed MM, Talaat RM, Sakr MA, Khalifa MK, Keshk MA, Ahmed EA, Selim MA, Abdelmonam SM, Nasr GM, El Hamshary MO.   +9 more
europepmc   +1 more source

Erdheim-Chester disease associated with myeloid neoplasm: Clinical features, molecular landscape, and treatment outcomes. [PDF]

Hemasphere
Le Pogam A, Papo M, Hirsch P, Cohen-Aubart F, Emile JF, Delhommeau F, Duffau P, Razanamahery J, Nguyen-Khac F, Nunes Gomes C, Triboulet F, de La Rochefoucauld J, McAvoy C, Lazaro E, Hage-Sleiman M, Roos-Weil D, Chasset F, Jachiet V, Mekinian A, Fain O, Amoura Z, Hadjadj J, Haroche J.   +22 more
europepmc   +1 more source

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy. [PDF]

Blood Adv
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD.   +28 more
europepmc   +1 more source

A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. [PDF]

Discov Oncol
Zeng S, Deng H, Dong H, Huang C, Ruan R, Dai X, Xiong J, Deng J, Yao Y.   +8 more
europepmc   +1 more source